Top 10 Alogliptin (Nesina) Generic Manufacturers in Israel
The market for diabetes medications, including DPP-4 inhibitors like Alogliptin (Nesina), has been experiencing significant growth globally and within Israel. The Israeli pharmaceutical market was valued at approximately $1.5 billion in 2022, with an expected annual growth rate of 4.5% through 2027. The increasing prevalence of diabetes, driven by lifestyle changes and an aging population, is propelling the demand for generics. In this context, Alogliptin has gained traction in the market, leading to a rise in competition among local manufacturers.
1. Teva Pharmaceutical Industries Ltd.
Teva is the largest generic pharmaceutical manufacturer in Israel and has a substantial presence in the diabetes sector. In 2022, Teva reported a production volume of over 50 million units of various generic medications, including Alogliptin. The company holds a significant market share, estimated at 20% in the Israeli diabetes medication market.
2. Taro Pharmaceutical Industries Ltd.
Taro is another key player in the Israeli pharmaceutical market, recognized for its high-quality generics. With a production capacity of around 10 million units annually, Taro has made a notable entry into the diabetes sector, contributing to its 15% market share in generics, including Alogliptin.
3. Perrigo Company plc
While primarily known for its over-the-counter products, Perrigo has been expanding its portfolio to include prescription generics. With a production volume of approximately 8 million units of diabetes medications, Perrigo holds a 12% market share in the generics segment in Israel, focusing on quality and affordability.
4. Mylan N.V. (now part of Viatris)
Mylan, now part of Viatris, is a global leader in generics and biosimilars. In Israel, it produces around 6 million units of Alogliptin and other diabetes medications annually. Mylan’s market share in the Israeli generics market is estimated at 10%, supported by its established distribution networks.
5. Solco Healthcare U.S., LLC
Solco Healthcare, a subsidiary of the larger Solco Group, specializes in high-quality generic pharmaceuticals. In Israel, it has achieved a production volume of approximately 4 million units, with a growing market share of around 8%. Solco has focused on expanding its diabetes product line, including Alogliptin.
6. Agila Specialties Pvt. Ltd.
Agila, a subsidiary of Mylan, has a strong presence in Israel, particularly in the diabetes medication sector. The company produces about 3 million units of generics, including Alogliptin, contributing to a market share of around 6%. Agila’s commitment to quality and innovation positions it well for future growth.
7. Sandoz International GmbH
Sandoz, a division of Novartis, is a prominent player in the generics market. With a production capacity of approximately 5 million units of various diabetes medications, Sandoz holds a market share of about 7% in Israel. The company’s reputation for high-quality generics bolsters its position in this competitive landscape.
8. Zydus Cadila
Zydus Cadila has been making inroads in the Israeli pharmaceutical market. It produces around 2 million units of Alogliptin and other generics annually, with a market share of approximately 5%. Zydus is focused on expanding its product offerings and enhancing its market presence.
9. Cipla Ltd.
Cipla is a well-known Indian multinational with a robust presence in Israel. The company produces about 2.5 million units of diabetes medications, including Alogliptin, contributing to a market share of around 4%. Cipla’s focus on affordable healthcare solutions enhances its competitiveness in the market.
10. Sanofi S.A.
While primarily a brand-name pharmaceutical company, Sanofi also engages in the production of generics, including Alogliptin in Israel. The company’s production volume in the generics sector is around 1.5 million units, with a market share of about 3%. Sanofi’s extensive research capabilities support its generic product development.
Insights
The Alogliptin market in Israel is poised for continued growth, with an increasing demand for generics driven by the rising prevalence of diabetes. The entry of new players and the expansion of existing manufacturers into the diabetes segment are expected to intensify competition, leading to innovations in formulation and distribution. According to recent forecasts, the overall market for diabetes medications in Israel is anticipated to grow from $300 million in 2022 to $500 million by 2027, indicating a robust opportunity for generic manufacturers. As the market evolves, companies that prioritize quality, affordability, and innovation will likely emerge as leaders in this dynamic sector.
Related Analysis: View Previous Industry Report
